Are we doing enough to reduce LDL? Hyperlipidemia Takes Center Stage at C3

Interventional Academy Speaks with Dr. Dinesh Kalra from Rush University, Chicago about Hyperlipidemia Sessions at C3

A recent publication by Buchholz et al examined national data on Cholesterol screening and awareness. National Health and Nutrition Examination Survey data for the 0.47% of surveyed adults with definite or probable familial hypercholesterolemia and the 6.6% overall with 190 mg/dL or higher low-density lipoprotein levels showed “uniformly low” levels of statin use, at 52.3% and 37.6%, respectively.

Since the discovery of PCSK9 inhibitors almost 10 years ago and the recent data showing reduction of cardiovascular outcomes with two commercially available agents, clinicians now have a way to drive down LDL-cholesterol levels to values previously unattainable with statins alone.

These drugs represent not only a major advance in reducing the residual risk with secondary prevention of patients with established atherosclerotic disease, but also a triumph of molecular medicine wherein the path from discovery of an heretofore unknown molecule to its successful pharmacological inhibition with recombinant monoclonal antibody techniques took under 10 years. There is much excitement about this pace of drug discovery, as well as of the long-term benefits that will accrue from high potency LDL lowering with these antibodies. Nonetheless, as with any new class of drugs, may questions remain – is an affordable proposition if the drugs were made available to all those who qualify? Is there a role in primary prevention? Is the LDL lowering achieved from these drugs as beneficial as that achieved by statins? Will any long-term safety signals change the risk benefit ratio?

Stay tuned for all of these cutting-edge advances and data to be presented at the C3 conference June 17-20 this year in Orlando. World renowned experts will share their algorithms on best to use these and other lipid lowering drugs, discuss drugs in the pipeline for dyslipidemias, and review their most difficult case examples. Don’t miss what will be an exciting session, packed with practical tips that every cardiologist and Primary care physician must know!

Leave a Reply

Your email address will not be published. Required fields are marked *